Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4A11 | Q02928 | 5/20 | 0.55 |
| ▸ | CYP4F2 | P78329 | 4/20 | 0.50 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | SPHK1 | Q9NYA1 | 7/20 | 0.41 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8573554 | 0.90 | CYP4A11 (0.53) | CYP4A11CYP4F2PPARACA2ESR1 | |
| SCHEMBL7252180 | 0.81 | KMT2A (0.48) | CA2ESR1ESR2 | |
| SCHEMBL3309903 | 0.79 | ESR1 (0.49) | ESR1ESR2 | |
| SCHEMBL8437707 | 0.78 | CYP4A11 (0.58) | CYP4A11CYP4F2PPARACA2ESR1 | |
| SCHEMBL8667512 | 0.78 | CYP4F2 (0.53) | CYP4A11CYP4F2ESR1ESR2 | |
| SCHEMBL18358078 | 0.75 | TSHR (0.42) | ESR1ESR2 | |
| SCHEMBL7904948 | 0.75 | ALDH1A1 (0.51) | CYP4A11CYP4F2ESR1ESR2 | |
| SCHEMBL12733081 | 0.75 | F2 (0.39) | CYP4A11CYP4F2 | |
| SCHEMBL9620180 | 0.74 | SLC6A3 (0.47) | ESR1ESR2 | |
| SCHEMBL8252300 | 0.74 | L3MBTL1 (0.45) | ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230330065-A1 | RelA Inhibitors for Biofilm Disruption | DREXEL UNIVERSITY (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230330065-A1 | RelA Inhibitors for Biofilm Disruption | DREXEL UNIVERSITY (US) | 2023-10-19 | — | — | US | disclosed |
| US-11666555-B2 | RelA inhibitors for biofilm disruption | DREXEL UNIVERSITY (US) | 2023-06-06 | — | — | US | disclosed |
| US-11666555-B2 | RelA inhibitors for biofilm disruption | DREXEL UNIVERSITY (US) | 2023-06-06 | — | — | US | disclosed |
| US-20200069647-A1 | RelA Inhibitors for Biofilm Disruption | DREXEL UNIVERSITY (US) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11666555-B2 | RelA inhibitors for biofilm disruption | RELA, NFKBIA, NFKB1 | CYP4A11 3722/4885CYP4F2 4349/4885PPARA 3709/4885 |
| US-20230330065-A1 | RelA Inhibitors for Biofilm Disruption | RELA, NFKBIA, NFKB1 | CYP4A11 3722/4885CYP4F2 4349/4885PPARA 3709/4885 |
| US-20200069647-A1 | RelA Inhibitors for Biofilm Disruption | RELA, NFKBIA, NFKB1 | CYP4A11 3722/4885CYP4F2 4349/4885PPARA 3709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.